Nvidia, the leading chipmaker, has made substantial investments in five tech stocks that are gaining attention in the market. The company’s recent 13F filing revealed its strategic positions in these companies, instilling confidence in their future prospects.
Nvidia’s share price has soared over 220% in the last year, driven by the AI boom. The company’s investments in smaller tech firms, such as SoundHound, are a testament to its ability to identify growth opportunities and support emerging players in the market.
These strategic investments carry significant implications and offer valuable insights for investors aiming to align with Nvidia’s success.
Arm Holdings (ARM)
Arm Holdings, a British semiconductor producer, has witnessed exceptional growth since going public in September 2023, with its stock surging over 107% in the last six months. Nvidia’s attempt to acquire Arm in a $40 billion deal in 2020, motivated by the soaring demand for graphic processing units (GPUs), underscores the synergies between the two companies. Though the acquisition was impeded by antitrust pressure, Nvidia’s considerable stake in Arm Holdings, as revealed in its 13F filing, speaks volumes about its long-term vision for the company.
Nano-X Imaging (NNOX)
Nano-X Imaging, a medical imaging company, has gained momentum following Nvidia’s investment. Despite being the smallest position in Nvidia’s 13F filing, Nano-X Imaging has experienced a significant surge in its stock price, indicating potential for further growth. This strategic investment by Nvidia, likely made during a market downturn, reinforces the company’s astute investment choices and market understanding. With projections for the medical imaging market reaching $61.51 billion by 2030, Nano-X Imaging holds promise for substantial future expansion, effectively validated by Nvidia’s vote of confidence.
Recursion Pharmaceuticals (RXRX)
Source: MacroEcon / Shutterstock.com
Under the table of companies Nvidia believes in is Recursion Pharmaceuticals (NASDAQ:RXRX) a biotech company. And like a savvy investor, the much-maligned drug industry just might have turned a corner. Said to make a return on that investor’s bet, at a time when many pull out, things are looking up. And what was recently smelled of disappointment is now in the air, filled with promise to be satisfied. Moreover, industry experts see the sector poised to grab headlines and enthuse backers looking for a company to get wrapped up in. And with the enthusiasm for the NK-1 receptor as a promising new direction, plenty of reasons exist for anticipation. That in the place where many find rancor, seems to be a change of tune, doesn’t it?
Nvidia Makes Unusual Bets on AI Stocks
Source: Piotr Swat / Shutterstock.com
The incorporation of Recursion Pharmaceuticals (NASDAQ:RXRX) into Nvidia’s portfolio might seem like an incongruous move, given its non-tech positioning. Yet, overlooked by some observers, the company adds a unique dimension to Nvidia’s investment strategy. Leveraging the power of AI, Recursion Pharmaceuticals has been providing valuable support to its counterparts in the genomics and biotech domains. The pharmaceutical innovator has witnessed consistent growth over the past year, with its shares nearly doubling since the outset of 2023. Notably, Nvidia has amassed 7,706,363 RXRX shares, making it the largest holding in this investment category.
AI in the Biotech Space
Today, while RXRX shares may not have skyrocketed as steeply as NNOX, they displayed a gradual upward trajectory. Besides Nvidia, distinguished contrarian investor, Cathie Wood of Ark Invest, recognized the potential of RXRX, adding 74,000 shares of its stock to the holdings in the ARK Genomic Revolution ETF (BATS:ARKG). The rolling bandwagon of prominent names aligning themselves with Recursion speaks volumes about the company’s burgeoning reputation.
Nvidia’s Leap into SoundHound AI (SOUN)
Source: rafapress / Shutterstock.com
Amid the fervor over AI, SoundHound AI has struggled to gain real traction. Despite its modest growth during the AI expansion, it has faced challenges in demonstrating substantial progress. Nonetheless, Nvidia’s investment catapulted SOUN stock by over 50% today, albeit it still treads in the penny stock territory. InvestorPlace contributor Jeremy Flint ventured that:
“SoundHound AI is a small-cap AI stock that may not stay small for long. The company is bringing AI into oft-overlooked fields within voice recognition, like helping restaurant operations improve order flow through AI voice assistance. Voice recognition is a small but growing field, and as AI stocks like SOUN show us, the total addressable market is as wide as a company can adapt its tech to serve.”
Flint’s analogized SoundHound to the next Palantir Technologies (NYSE:PLTR), aligning with Nvidia’s endorsement through its acquisition of 1,730,883 shares of SOUN stock to bolster the company’s standing in the investment arena.
An Unexpected Play on TuSimple Holdings (TSPH)
Source: Robert Way / Shutterstock.com
Nvidia’s interest in this Chinese autonomous trucking technology company, TuSimple (OTCMKTS:TSPH), certainly raised eyebrows, given its status as a microcap stock. Valued at just over $105 million, TSPH is even lower down the price ladder than SoundHound. Despite a surge of almost 35%, TSPH still sits at a mere $0.48 per share. However, with Nvidia acquiring 3,465,372 TuSimple shares, amidst its relentless downward spiral over the past six months, Nvidia’s bullish outlook on its growth potential comes to the fore.
Notably, TuSimple secured a significant milestone in June 2023, becoming the first company to operate a fully autonomous semi-truck on China’s open road. With a strong foothold in both the United States and China, TuSimple is strategically positioned to harness a slice of the rapidly expanding market.
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day due to their susceptibility to market manipulation. Readers are advised to cautiously approach investments in such stocks.
Read More: Penny Stocks — How to Profit Without Getting Scammed
On the date of publication, Samuel O’Brient did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines. Samuel O’Brient is a Reporter for InvestorPlace, where his work focuses primarily on financial markets, global economic trends, and public policy.
